Consistent with reported data, FLT3 is almost exclusively expressed in the hematopoietic compartment, and the FLT3-ITD mutation level has been used as a prognostic marker for the treatment of patients with AML [41–43]. The gene discussed is FLT3; the disease is acute myeloid leukemia.